West Pharmaceutical (WST) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $2.37
- EPS estimate
- $2.08
- EPS surprise
- +13.86%
- Revenue surprise
- +3.85%
- Revenue
- $872.3M
- Revenue estimate
- $840.0M
- Reported
- Jul 23, 2026
West Pharmaceutical reported Q2 2026 results on July 23, 2026. Earnings per share came in at $2.37, ahead of the $2.08 estimate by 13.86%. Revenue was $872.3 million, above the $840.0 million consensus by 3.85%. Compared with Q2 2025, EPS rose about 29% from $1.84 and revenue rose about 14% from $766.5 million. Revenue was a high for the table.
The longer record shows a dip and a recovery. Annual EPS fell from $8.57 in 2022 to $8.08 in 2023 and $6.75 in 2024, then rose to $7.29 in 2025. The first half of 2026 adds up to $4.50, about 37% more than the same period a year earlier. Q1 2025 was the low point in the table at $1.45 per share. The EPS high remains Q2 2022, at $2.47. Over the last 20 quarters, West Pharmaceutical topped the EPS estimate 18 times. The two misses were Q3 2022, at 4.25% below, and Q2 2024, at 12.70% below.
West Pharmaceutical reported Q3 between October 23 and October 28 in each of the past five years. That points to late October 2026 for the next report. It will show whether the year-over-year growth seen in recent quarters continues.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 23, 2026 | $2.08 | $2.37 | +13.86% | $872.3M | SEC |
| Q1 2026 | Apr 23, 2026 | $1.68 | $2.13 | +26.94% | $844.9M | SEC |
| Q4 2025 | Feb 12, 2026 | $1.83 | $2.04 | +11.62% | $805.0M | SEC |
| Q3 2025 | Oct 23, 2025 | $1.68 | $1.96 | +16.33% | $804.6M | SEC |
| Q2 2025 | Jul 24, 2025 | $1.51 | $1.84 | +21.92% | $766.5M | SEC |
| Q1 2025 | Apr 24, 2025 | $1.23 | $1.45 | +18.13% | $698.0M | SEC |
| Q4 2024 | Feb 13, 2025 | $1.72 | $1.82 | +5.87% | $748.8M | SEC |
| Q3 2024 | Oct 24, 2024 | $1.50 | $1.85 | +23.28% | $746.9M | SEC |
| Q2 2024 | Jul 25, 2024 | $1.74 | $1.52 | −12.70% | $702.1M | SEC |
| Q1 2024 | Apr 25, 2024 | $1.27 | $1.56 | +22.51% | $695.4M | SEC |
| Q4 2023 | Feb 15, 2024 | $1.78 | $1.83 | +2.91% | $732.0M | SEC |
| Q3 2023 | Oct 26, 2023 | $1.86 | $2.16 | +16.34% | $747.4M | SEC |
| Q2 2023 | Jul 27, 2023 | $1.93 | $2.11 | +9.53% | $753.8M | SEC |
| Q1 2023 | Apr 27, 2023 | $1.67 | $1.98 | +18.68% | $716.6M | SEC |
| Q4 2022 | Feb 16, 2023 | $1.38 | $1.77 | +28.66% | $708.7M | SEC |
| Q3 2022 | Oct 27, 2022 | $2.12 | $2.03 | −4.25% | $686.9M | SEC |
| Q2 2022 | Jul 28, 2022 | $2.21 | $2.47 | +11.89% | $771.3M | SEC |
| Q1 2022 | Apr 28, 2022 | $2.12 | $2.30 | +8.32% | $720.0M | SEC |
| Q4 2021 | Feb 17, 2022 | $1.92 | $2.04 | +6.50% | $730.8M | SEC |
| Q3 2021 | Oct 28, 2021 | $1.80 | $2.06 | +14.65% | $701.0M | SEC |
Quarterly revenue
Frequently asked questions
When did West Pharmaceutical (WST) last report earnings?
West Pharmaceutical last reported on Jul 23, 2026, covering fiscal Q2 2026.
Did WST beat earnings estimates?
Yes. West Pharmaceutical reported EPS of $2.37 for Q2 2026 against a $2.08 estimate — a 13.86% beat.
How much revenue did WST report last quarter?
West Pharmaceutical reported $872.3M in revenue for Q2 2026, against a consensus estimate of $840.0M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.